SCHEMBL7126403

SCHEMBL7126403

COc1ccc(OC)c(C(=O)C2CCC(OC)CC2c2ccc(F)c(O)c2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.40
MAPT P10636 3/20 0.40
HTT P42858 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38
CPS1 P31327 4/20 0.38
TUBB4A P04350 3/20 0.37
TUBB P07437 3/20 0.37
TUBA3C P0DPH7 3/20 0.37
TUBA1B P68363 3/20 0.37
TUBA4A P68366 3/20 0.37
TUBB4B P68371 3/20 0.37
TUBB3 Q13509 3/20 0.37
TUBB2A Q13885 3/20 0.37
TUBB8 Q3ZCM7 3/20 0.37
TUBA3E Q6PEY2 3/20 0.37
TUBA1A Q71U36 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7127003 0.94 LMNA (0.40) LMNAMAPTHTTKDM4EALDH1A1
SCHEMBL6859799 0.93 TUBB4A (0.44) LMNAMAPTHTTKDM4EALDH1A1
SCHEMBL7127027 0.91 LMNA (0.44) LMNAMAPTHTTKDM4EALDH1A1
SCHEMBL7115907 0.90 MAPT (0.46) LMNAMAPTHTTKDM4EALDH1A1
SCHEMBL7117523 0.90 MAPT (0.40) LMNAMAPTHTTKDM4EALDH1A1
SCHEMBL6861039 0.89 MAPT (0.40) LMNAMAPTHTTKDM4EALDH1A1
SCHEMBL7125930 0.88 MAPT (0.46) LMNAMAPTHTTKDM4EALDH1A1
SCHEMBL7125634 0.87 MAPT (0.41) LMNAMAPTHTTKDM4EALDH1A1
SCHEMBL7117399 0.86 LMNA (0.42) LMNAMAPTHTTKDM4EALDH1A1
SCHEMBL6853125 0.86 TUBB4A (0.44) LMNAMAPTHTTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030149072-A1 Substituted arylcycloalkanes, compositions containing them and use thereof AVENTIS PHARMA S.A. (FR) 2003-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149072-A1 Substituted arylcycloalkanes, compositions containing them and use thereof ABL1, MCL1, AHR LMNA 3280/4885MAPT 4538/4885HTT 2064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.